Gene Therapy for Glioblastoma Multiforme

Viruses, Journal Year: 2025, Volume and Issue: 17(1), P. 118 - 118

Published: Jan. 16, 2025

Glioblastoma multiforme (GBM) is a devastating, aggressive primary brain tumor with poor patient outcomes and five-year survival of less than 10%. Significant limitations to effective GBM treatment include drug delivery across the blood–brain barrier, resistance, complex genetic alterations. Gene therapy uses mechanism different from other therapies reduce growth enhance antitumor immunity. This review article will provide an update on various viral nonviral vectors, their DNA RNA cargoes, how they genetically modify cells evoke therapeutic responses GBM. The explores oncolytic immunogenic effects gene agents. It reviews promising transgenes, inhibitors, vectors for anti-GBM therapy. possible benefits combining standard treatments also be covered.

Language: Английский

Matrix metallopeptidase 2-responsive curcumin-loaded nanoparticles-induced signal transducer and activator of transcription 3 inhibition suppresses glioblastoma multiforme growth via enhancing nuclear factor erythroid 2-related factor 2 activity

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 307, P. 141998 - 141998

Published: March 11, 2025

This study investigated the inhibitory effects of matrix metallopeptidase 2 (MMP2)-responsive curcumin-loaded nanoparticles on glioblastoma multiforme (GBM), and elucidated their underlying mechanisms. The methods employed included Cell Counting Kit-8 viability assay, colony formation flow cytometry for apoptosis analysis, wound healing migration quantitative real-time polymerase chain reaction, western blotting gene expression profiling, mitochondrial function assessment, in vivo antitumor efficacy evaluation. Curcumin significantly reduced viability, proliferation, migratory capacity murine glioma cells (GL261). It also induced apoptosis, disrupted function, increased reactive oxygen species levels. Notably, curcumin upregulated nuclear factor erythroid 2-related (Nrf2) while inhibiting signal transducer activator transcription 3 (STAT3) activation. synthesized MMP2-responsive (Cur-NPs) effectively suppressed tumor growth prolonged survival a GBM mouse model. These data suggest that inhibits STAT3 activity via an Nrf2-dependent mechanism. advances our understanding mechanism action suggests potential avenues development targeted therapies GBM.

Language: Английский

Multifunctional nanoplatforms based on RNA interference for glioma treatment

American Journal of Cancer Research, Journal Year: 2025, Volume and Issue: 15(3), P. 835 - 854

Published: Jan. 1, 2025

Glioma is the most common malignant tumor in central nervous system. Currently, clinical treatments for glioma include surgery, radiation therapy, chemotherapy and immunotherapy, among which combination of immunotherapy has attracted wide attention. However, ability chemotherapeutic agents immune checkpoint blockers to reach gliomas limited due existence blood brain/tumor barrier (BBB/BTB). RNA interference (RNAi) technology enables specific silencing target genes associated with cancer so it been used as an emerging potential treatment strategy. Small (siRNA) easily degraded by serum endonuclease, can be quickly filtered cleared glomerulus. Therefore, design construction safe effective delivery systems conducive improving stability siRNA efficiency gene silencing. This review focuses on research progress nano system based treatment.

Language: Английский